Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | PARG | Q86W56 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28341902 | 0.82 | DDB1 (0.41) | NR1H2USP30RORCGPR119 | |
| SCHEMBL12101515 | 0.82 | FFAR1 (0.51) | NR1H2NAMPTPARGUSP30JAK3 | |
| SCHEMBL15272864 | 0.80 | SRC (0.31) | — | |
| SCHEMBL25193692 | 0.79 | JAK3 (0.43) | NR1H2NAMPTPARGUSP30JAK3 | |
| SCHEMBL3597987 | 0.79 | NR1H2 (0.43) | NR1H2NAMPTPARGUSP30JAK3 | |
| SCHEMBL31546905 | 0.79 | NR1H2 (0.40) | NR1H2NAMPTPARGUSP30JAK3 | |
| SCHEMBL18764769 | 0.78 | L3MBTL1 (0.45) | NR1H2NAMPTUSP30JAK3GPR119 | |
| SCHEMBL31553919 | 0.78 | KDM4E (0.35) | JAK3 | |
| SCHEMBL15273525 | 0.78 | TBK1 (0.30) | NR1H2NAMPT | |
| SCHEMBL15647731 | 0.78 | ROCK2 (0.39) | NR1H2USP30RORCGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745010-B1 | SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2009-08-05 | — | — | EP | claimed |
| US-8507489-B2 | Bicyclic triazoles as protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2084162-B1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8071581-B2 | Triazolopyridazine protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-10-15 | — | — | US | disclosed |
| EP-2084162-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2081937-A2 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008051805-A2 | TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051808-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | MAP4K5, MAPKAPK5, MAP4K2 | NR1H2 1926/4885NAMPT 1983/4885PARG 4809/4885 |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | MAP3K20, TTK, PRKACB | NR1H2 2739/4885NAMPT 1838/4885PARG 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.